Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma

Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma

We have previously shown that ablative radiotherapy (A-RT) with a biologically effective dose (BED<sub>10</sub>) ≥ 80.5 Gy for patients with unresectable intrahepatic cholangiocarcinoma (ICC) is associated with longer survival. Despite recent large-scale sequencing efforts in ICC, outcom...

Full description

Bibliographic Details
Main Authors: Brian De, Ibrahim Abu-Gheida, Aashini Patel, Sylvia S. W. Ng, Mohamed Zaid, Connor P. Thunshelle, Dalia Elganainy, Kelsey L. Corrigan, Michael K. Rooney, Milind Javle, Kanwal Raghav, Sunyoung S. Lee, Jean-Nicolas Vauthey, Ching-Wei D. Tzeng, Hop S. Tran Cao, Ethan B. Ludmir, Bruce D. Minsky, Grace L. Smith, Emma B. Holliday, Cullen M. Taniguchi, Albert C. Koong, Prajnan Das, Eugene J. Koay
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Journal of Personalized Medicine
Subjects:
cholangiocarcinoma
mutation
genetic
genomic
radiotherapy
Online Access:https://www.mdpi.com/2075-4426/11/12/1270

Internet

https://www.mdpi.com/2075-4426/11/12/1270

Similar Items